The United States Congress in 2001 recognized the need to bridge the gap between pure science and patient care and to provide translational research for the rapid development of new technologies in molecular or “personalized medicine” to significantly advance the early detection, diagnosis, and treatment of cancer and other diseases, and established The National Functional Genomics Center (NFGC) (Public Law 107-117).